Global Alpha-1 Antitrypsin Drugs Market to Grow at a CAGR of 35.42% between 2016-2020 Market Research Report
1. Title:
Global Alpha-1 Antitrypsin Drugs Market to Grow at a CAGR of 35.42% between
2016-2020 Market Research Report
Short Summary
Global Alpha-1 Antitrypsin Drugs Market 2016-2020 Size and Share Published in
2016-04-27 Available for US$ 2500 at Researchmoz.us
Description
Alpha-1 antitrypsin, also known as an alpha-1 protease inhibitor (A1PI), is a glycoprotein
produced in the liver that helps in the inactivation of enzymes such as elastase, which break
down proteins during inflammation induced by some injury. The decline in alpha-1
antitrypsin levels in the blood results in a rare genetic condition known as alpha-1
antitrypsin deficiency (AATD), which leads to the development of respiratory and liver
diseases, and severe skin infections. The disease is passed on from parents to an offspring
through mutated genes. Augmentation therapy using drugs derived from human plasma
helps in maintaining levels of alpha-1 antitrypsin in the blood, helping in remission of the
condition.
Technavios analysts forecast the global alpha-1 antitrypsin drugs market to grow at a CAGR
of 35.42% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global alpha-1
antitrypsin drugs market for 2016-2020. To calculate the market size, the report considers
the revenue generated from the sales of branded drugs and off-label drugs used for the
symptomatic treatment of diseases occurring due to alpha-1 antitrypsin deficiency and other
disorders.
The market is divided into the following segments based on geography:
Americas
APAC
EMEA
Get a Free Sample Copy of the Report: http://www.researchmoz.us/enquiry.php?
type=S&repid=715921
Technavio's report, Global Alpha-1 Antitrypsin Drugs Market 2016-2020, has been prepared
based on an in-depth market analysis with inputs from industry experts. The report covers
the market landscape and its growth prospects over the coming years. The report also
includes a discussion of the key vendors operating in this market.
Key vendors
Baxter International
CSL Behring
2. Grifols
Kamada
Other prominent vendors
Abeona Therapeutics
Alnylam Pharmaceuticals
Applied Genetic Technologies
Arrowhead Research
Baxalta
Biogen
Chiesi
Curaxys
Laboratoire franais du Fractionnement et des Biotechnologies
ProBioGen
ProMetic Life Sciences
Market driver
Improved diagnosis of alpha-1 antitrypsin deficiency (AATD)
For a full, detailed list, view our report
Market challenge
Limited plasma fractionation capacity
For a full, detailed list, view our report
Market trend
Increasing awareness about therapy
For a full, detailed list, view our report
Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
3. What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analysts time when you purchase this market report.
Details are provided within the report.
Inquiry on this report: http://www.researchmoz.us/enquiry.php?
type=E&repid=715921
Table of Content
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Overview: Alpha-1 antitrypsin deficiency
Pathophysiology
Symptoms
Diagnosis
Management
Browse All Cardiovascular Devices Market Research Reports at:
http://www.researchmoz.us/cardiovascular-devices-market-reports-61.html
About ResearchMoz
